The case for inhibiting p38 mitogen-activated protein kinase in heart failure
This minireview discusses the evidence that the inhibition of p38 mitogen-activated protein kinases (p38 MAPKs) maybe of therapeutic value in heart failure. Most previous experimental studies, as well as past and ongoing clinical trials, have focussed on the role of p38 MAPKs in myocardial infarctio...
Saved in:
Main Authors: | Pelin eArabacilar (Author), Michael eMarber (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2015-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
by: Haichuan Yu, et al.
Published: (2022) -
p38 Mitogen-Activated Protein Kinase Regulates Vasoconstriction in Spontaneously Hypertensive Rats
by: Seongchun Kwon, et al.
Published: (2004) -
Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses
by: Yanyan Yang, et al.
Published: (2014) -
p38 Mitogen-Activated Protein Kinase Mediates Sidestream Cigarette Smoke-Induced Endothelial Permeability
by: Brad Low, et al.
Published: (2007) -
S-deoxydihydroglyparvin from Glycosmis parva inhibits lipopolysaccharide induced murine macrophage activation through inactivating p38 mitogen activated protein kinase
by: Chanyanuch Laprasert, et al.
Published: (2021)